Skip to main content

Table 2 Multivariate analysis of recurrence after curative hepatectomy for patients with BCLC 0/A stage HCC

From: Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma

Variable

Comparison

All (n = 820)

CHB (n = 458)

CHC (n = 284)

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age (years)

>60 vs. ≦ 60

1.291 (1.064–1.566)

0.010

    

Sex

Male vs. Female

      

AFP (ng/mL)

>200 vs. ≦ 200

      

Liver cirrhosis

Yes vs. No

1.743 (1.437–2.113)

< 0.001

1.991 (1.530–2.592)

< 0.001

1.617 (1.187–2.203)

0.002

Diabetes

Yes vs. No

1.418 (1.147–1.755)

0.001

1.823 (1.343–2.475)

< 0.001

  

Child-Pugh grade

B vs. A

      

Tumor number

Multiple vs. Single

1.750 (1.304–2.348)

< 0.001

1.582 (1.085–2.305)

0.017

2.091 (1.292–3.385)

0.003

Tumor size (cm)

>2 vs. ≦ 2

1.406 (1.113–1.774)

0.004

1.716 (1.221–2.411)

0.002

  

Histology stages

Poor vs. well + moderate

      

Vascular invasion

Yes vs. No

1.659 (1.364–2.018)

< 0.001

1.464 (1.120–1.913)

0.005

1.776 (1.309–2.409)

< 0.001

Statin

Yes vs. No

0.354 (0.210–0.599)

< 0.001

0.393 (0.181–0.854)

0.018

  

NSAIDs

Yes vs. No

      

Aspirin

Yes vs. No

      

Metformin

Yes vs. No

      

Antiviral therapy

Yes vs. No

0.613 (0.503–0.748)

< 0.001

    

NA therapy

Yes vs. No

  

0.590 (0.453–0.768)

< 0.001

  

HCV therapy

Yes vs. No

    

0.496 (0.361–0.682)

< 0.001

  1. NSAIDs Nonsteroidal anti-inflammatory drugs, NA therapy Nucleos(t)ide analogues
  2. HCV therapy included interferon and direct-acting antiviral medications